GSK stops aplaviroc trials

GlaxoSmithKline (LSE:GSK; GSK) stopped a placebo-controlled Phase II trial of aplaviroc (873140) in 250 treatment-naive HIV patients after two patients had an elevation in liver enzyme levels and bili...